Display options
Cite
Krawczyk P, Jarosz B, Kucharczyk T, et al. Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of . Oncotarget. 2017;8(38):64283-64293doi: 10.18632/oncotarget.19724.
Krawczyk, P., Jarosz, B., Kucharczyk, T., Grenda, A., Reszka, K., Pankowski, J., Wojas-Krawczyk, K., Nicoś, M., Szumiło, J., Trojanowski, T., & Milanowski, J. (2017). Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of . Oncotarget, 8(38), 64283-64293. https://doi.org/10.18632/oncotarget.19724
Krawczyk, Paweł, et al. "Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of ." Oncotarget vol. 8,38 (2017): 64283-64293. doi: https://doi.org/10.18632/oncotarget.19724
Krawczyk P, Jarosz B, Kucharczyk T, Grenda A, Reszka K, Pankowski J, Wojas-Krawczyk K, Nicoś M, Szumiło J, Trojanowski T, Milanowski J. Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of . Oncotarget. 2017 Jul 31;8(38):64283-64293. doi: 10.18632/oncotarget.19724. eCollection 2017 Sep 08. PMID: 28969070; PMCID: PMC5610002.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jul 31;8(38):64283-64293. doi: 10.18632/oncotarget.19724. eCollection 2017 Sep 08.

Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of .

Oncotarget

Paweł Krawczyk, Bożena Jarosz, Tomasz Kucharczyk, Anna Grenda, Katarzyna Reszka, Juliusz Pankowski, Kamila Wojas-Krawczyk, Marcin Nicoś, Justyna Szumiło, Tomasz Trojanowski, Janusz Milanowski

Affiliations

  1. Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland.
  2. Department of Neurosurgery and Pediatric Neurosurgery, Medical University of Lublin, Lublin, Poland.
  3. Genetics and Immunology Laboratory, Genim LLC, Lublin, Poland.
  4. Department of Pathology, Pulmonary Hospital, Zakopane, Poland.
  5. Department of Pathomorphology, Medical University of Lublin, Lublin, Poland.

PMID: 28969070 PMCID: PMC5610002 DOI: 10.18632/oncotarget.19724

Abstract

Different immunohistochemical (IHC) assays were approved for PD-L1 expression examination on tumor cells in qualification to immune-checkpoint inhibitors therapy in NSCLC patients. These assays have some similarities, but also very serious differences. We assessed 2 IHC tests for PD-L1 expression evaluation in NSCLC tumors with different pathological diagnoses and genetic abnormalities. We enrolled 48 NSCLC patients (median age: 65 years) with known status of

Keywords: ALK; EGFR; PD-L1; non-small cell lung cancer

Conflict of interest statement

CONFLICT OF INTEREST All authors declare no conflict of interest.

References

  1. N Engl J Med. 2015 Oct 22;373(17):1627-39 - PubMed
  2. Science. 2015 Apr 3;348(6230):124-8 - PubMed
  3. Arch Pathol Lab Med. 2015 Dec;139(12):1477-8 - PubMed
  4. J Thorac Oncol. 2017 Feb;12 (2):208-222 - PubMed
  5. Arch Pathol Lab Med. 2016 Mar;140(3):249-54 - PubMed
  6. Ann Oncol. 2016 Jan;27(1):147-53 - PubMed
  7. J Thorac Oncol. 2017 May;12 (5):878-883 - PubMed
  8. JAMA Oncol. 2016 Jan;2(1):46-54 - PubMed
  9. Lancet Oncol. 2015 Mar;16(3):257-65 - PubMed
  10. Lancet. 2016 Apr 9;387(10027):1540-50 - PubMed
  11. Lancet. 2017 Jan 21;389(10066):255-265 - PubMed
  12. Lancet Oncol. 2017 Mar;18(3):271-273 - PubMed
  13. N Engl J Med. 2015 Jul 9;373(2):123-35 - PubMed
  14. N Engl J Med. 2015 May 21;372(21):2018-28 - PubMed
  15. Oncoimmunology. 2016 Mar 16;5(5):e1131379 - PubMed
  16. J Thorac Oncol. 2015 Jul;10(7):985-9 - PubMed
  17. Arch Pathol Lab Med. 2016 Apr;140(4):326-31 - PubMed
  18. Lancet. 2016 Apr 30;387(10030):1837-46 - PubMed

Publication Types